SINGAPORE, January 29, 2026 – Mirxes Holding Company Limited (“Mirxes” or the “Company”, Stock Code: 2629.HK), a leading and only publicly-listed molecular cancer early detection company in Asia Pacific, is pleased to announce it has entered into a placing agreement to issue 21,888,000 new shares. Facilitated by Joint Placing Agents CLSA Limited and CCB International Capital Limited, the placing is priced at HK$32.50 per share, representing a substantial 40% increase over the Company’s May 2025 IPO price.
Strategic Capital Injection
The placement, which has attracted strong investor demand and is oversubscribed, is expected to raise gross proceeds of approximately HK$711.36 million, prior to deducting relevant costs, commissions and levies.
The strategic drivers for this placement include funding capital-intensive, multi-year clinical programmes, securing multi-market regulatory approvals, and maintaining the agility to execute evolving business priorities. Mirxes intends to allocate the nett proceeds as follows:
- Investments and mergers & acquisitions activities (30%)
- Research and development, including clinical research across existing pipelines and development of new pipelines (25%)
- Expansion into emerging markets such as India (20%)
- General working capital purposes (25%)
Placement Details
The placing price of HK$32.50 per share represents:
- An 88% discount to the closing price of HK$36.88 on January 28, 2026 (the last trading day prior to the agreement).
- A 43% discount to the average closing price of HK$37.98 over the five consecutive trading days preceding the agreement.
The shares will be placed by the Placing Agents on a best-effort basis to no fewer than six independent professional and institutional investors. The new shares will be issued under the Company’s existing General Mandate and are not subject to further shareholder approval. The 21,888,000 placing shares represent approximately 7.92% of the total existing issued shares as of the announcement date and will account for approximately 7.34% of the total issued shares as enlarged by the issuance, assuming full subscription and no other changes to the share capital prior to closing.
Dr Zhou Lihan, Co-founder and CEO of Mirxes, said: “This first placement following our listing marks a pivotal step in Mirxes’ long-term growth strategy. The placement attracted strong demand from both institutional and strategic investors and is significantly oversubscribed, reflecting strong market confidence in Mirxes’ execution capabilities and the strength of our industry-leading microRNA detection platform. The additional capital strengthens our capacity to execute a multi-year innovation roadmap, advance clinical programmes and accelerate our expansion into key global markets. As we build the next chapter of Mirxes, we remain committed to translating scientific breakthroughs into accessible preventive healthcare for communities worldwide.”
About Mirxes
Founded in Singapore in 2014, Mirxes (2629.HK) is a leading RNA technology company dedicated to making cancer early detection solutions accessible. Leveraging our proprietary, industry-leading microRNA detection platform, we developed GASTROClear™, a regulatory-approved, first-in-class blood test for gastric cancer screening. We are also advancing a robust clinical pipeline of single and multi-cancer tests for high-incidence cancers including lung, colorectal, liver and breast cancers, in collaboration with renowned academic and clinical institutions globally. Complementary to our core cancer early detection tests, Mirxes also commercialises a strong portfolio of advanced PCR and NGS tests for both clinical oncology and biopharma discovery use, supported by integrated in-house R&D, medical device manufacturing, regulatory and CAP accredited clinical diagnostic capabilities. For more information, visit https://mirxes.com/ and follow us on LinkedIn, Facebook, and Instagram.
For media enquiries, please contact:
David Yeo
VP, Strategic Relations and Public Affairs, Mirxes
Email: davidyeo@mirxes.com
Mobile: +65-9030 1422